Original article. Assessment of biochemical changes among Egyptian women with increased body weight

Open access

Abstract

Background: Obesity is a condition that results from chronic disruption of energy balance where energy intake continuously exceeds energy expenditure and accumulation of body fat results

Objective: We evaluated the relationships between ghrelin and leptin with the metabolic state of normal weight, overweight, and obese Egyptian women.

Methods: We studied 82 subjects with ages from 43 to 65. They were free of endocrine-related disease and divided into three groups according to their body mass index (BMI), group 1 with BMI less than 25 kg/m2, group 2 with BMI between 25 to 30 kg/m2, and group 3 with BMI more than 30 kg/m2. Ghrelin and leptin were determined by ELISA technique. Insulin resistance was measured by homeostasis model assessment. Lipid profile was determined in all groups.

Results: Fasting plasma levels of ghrelin were lower in overweight and obese groups compared to normal weight control group. There was statistically significant negative correlation of ghrelin levels with leptin, BMI and HOMA. Results showed that higher concentrations of fasting leptin were found in overweight and obese groups compared with the normal weight control group. There was statistically significant positive correlation between leptin and other biochemical parameters, insulin, BMI, and HOMA.

Conclusion: Ghrelin and leptin may be associated with obesity. These markers can be of value when assessing management.

1. Hill JO. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev. 2006; 27:750-61.

2. Kopelman PG. Obesity as a medical problem. Nature. 2000; 404:635-43.

3. Abolfotouh MA, Soliman LA, Mansour EF, El- Dawaiaty A. Central obesity among adults in Egypt: prevalence and associated morbidity. East Mediterr Health J. 2008; 14:57-68.

4. Druce M, Bloom SR. The regulation of appetite. Arch Dis Child. 2006; 91:183-7.

5. Korbonits M, Grossman AB. Ghrelin: update on a novel hormonal system. Eur J Endocrinol. 2004;1(151 Suppl):S67-70.

6. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409:194-8.

7. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005; 85:495-522.

8. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86:5992.

9. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001; 50:2540-7.

10. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, Dieguez C. Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology. 2003; 144:544-51.

11. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707-9.

12. Williams DL, Grill HJ, Cummings DE, Kaplan JM. Overfeeding-induced weight gain suppresses plasma ghrelin levels in rats. J Endocrinol Invest. 2006; 29: 863-8.

13. Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology. 2010; 151:4745-55.

14. Brennan A, Mantzoros CS. Drug insight: the role of leptin in humanphysiology and pathophysiology - emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006; 2:318-27.

15. Margetic S, Gazzola C. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002; 26:1407-33.

16. Matarese G, Moschos S. Leptin in immunology. J Immunol. 2005; 174:3137-42.

17. Sinha MK, Ohannesian JP. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest. 1996; 97:1344-7.

18. Bluher S, Mantzoros CS. Leptin in humans: lessons from translational research. Am J Clin Nutr. 2009; 89: 991S-7S.

19. Considine RV, Sinha MK. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. New Engl J Med. 1996; 334:292-5.

20. Boden G, Chen X. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab. 1996; 81:3419-23.

21. Chan JL, Heist K. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003; 111:1409-21.

22. Gao Q, Horvath T. Cross-talk between estrogen and leptin signaling in the hypothalamus. Am J Physiol Endocrinol Metab. 2008; 294:E817-26.

23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DR, Turner D. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasmaglucose and insulin concentrations in man. Diabetologia. 1985; 28:412-9.

24. Foster-Schubert KE, McTiernan A, Frayo RS, Schwartz RS, Rajan KB, Yasui Y. Human plasma ghrelin levels increase during a one-yearexercise program. J Clin Endocrinol Metab. 2005; 90:820-5.

25. Trinder P. Determination of glucose in blood using glucoseoxidase with an alternative oxygen acceptor. Ann ClinBiochem. 1969; 6:24-6.

26. Albright SV, McCart JA, Libutti SK, Bartlett DL, Alexander HR, Sampson ML, et al. Rapid measurement of insulin using the Abbott IMx: applicationto the management of insulinoma. Ann ClinBiochem. 2002; 39:513-5.

27. Friedewald WT, Levy RI, Fredrickson DS. Estimationof the concentration of low-density lipoprotein cholesterol inplasma without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499-502.

28. Yada T, Dezaki K, Sone H, Koizumi M, Damdindorj B, Nakata M. Ghrelin regulates insulin release and glycemia: physiological roleand therapeutic potential. Curr Diabetes Rev. 2008; 4:18-23.

29. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without timeand food-related cues. Am J Physiol Endocrinol Metab. 2004; 287:E297-304.

30. Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab. 2004; 89:1319-24.

31. Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006; 89:71-84.

32. Davies JS, Kotokorpi P, Eccles SR, Barnes SK, Tokarczuk PF, Allen SK, et al. Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention. Mol Endocrinol. 2009; 23:914-24.

33. Purnell JQ, Weigle DS, Breen P, Cummings DE. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab. 2003; 88: 5747-52.

34. Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiol- ogy and treatment. Trends Endocrinol Metab. 2004; 15:12-20.

35. Zhu JF, Liang L, Zou CC, Fu JF. Plasma ghrelin levels and polymorphisms of ghrelin gene in Chinese obese children and adolescents. Ir J Med Sci. 2010; 179: 345-9.

36. Considine RV, Sinha MK, Murata M. Serum immunoreactive-leptinconcentrations in normal-weight and obese humans. New Engl J Med. 1996; 334:292-5.

37. Farooqi IS, Wangensteen T. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. New Engl J Med. 2007; 356:237-47.

38. Farooqi S. Insights from the genetics of severe childhood obesity. Horm Res. 2007; 68(Suppl. 5):5-7.

39. Vila R, Adan C. Plasma leptin turnover rates in lean and obese Zucker rats. Endocrinology. 1998; 139: 4466-9.

40. Ravussin E, Smith SR. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesitypharmacotherapy. Obesity (Silver Spring). 2009; 17:1736-43.

41. Remsberg K, Talbott E, Jeanne V, Zborowski D, Evans R, McHugh-Pemu. Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril. 2002; 78:476-87.

42. Chapman IM, Wittert GA, Norman RJ. Circulating leptin concentrationsin polycystic ovary syndrome: relation to anthropometric and metabolic parameters. Clin Endocrinol. 1997;46:175-81.

43. Haffner SM, Gingerich RL, Miettinen H, Stern MP. Leptin concentrationsin relation to overall adiposity and regional body fat distribution in Mexican Americans. Int J Obes Relat Metab Disord. 1996; 20: 904-8.

44. Mueller WM, Gregoire FM, Stanhope KL, Mobbs CV, Mizuno TM, Warden CH. Evidence that glucose metabolism regulates leptinsecretion from cultured rat adipocytes. Endocrinology. 1998; 139:551-8.

45. Mizuno TM, Bergen H, Funabashi T, Kleopoulos SP, Zhong YG, Bauman WA. Obese gene expression: reduction by fasting andstimulation by insulin and glucose in lean mice, and persistentelevation in acquired (diet-induced) and genetic (yellow agouti) obesity. Proc Natl Acad Sci. 1996; 93:3434-8.

46. Pratley RE, Ren K, Milner MR, Sell SM. Insulin increases leptinmRNA expression in abdominal subcutaneous adipose tissue in humans. Mol Genet Metab. 2000; 70:19-26.

47. Saad MF, Khan A, Sharma A, Michael R, Riad-Gabriel MG, Boyadjian R. Physiological insulinemia acutely modulates plasma leptin. Diabetes. 1998; 47:544-9.

Journal Information


IMPACT FACTOR 2017: 0.209
5-year IMPACT FACTOR: 0.243

CiteScore 2017: 0.24

SCImago Journal Rank (SJR) 2017: 0.162
Source Normalized Impact per Paper (SNIP) 2017: 0.173

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 93 78 5
PDF Downloads 41 38 3